Sun Pharmaceutical Industries Limited, in collaboration with Israel-based Moebius Medical Limited, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) for MM-II, a novel treatment targeting osteoarthritis knee pain. MM-II is formulated using large liposomes of DPPC and DMPC, which have shown potential in addressing the unmet medical …